Martin Schiestl obtained his PhD in chemistry with focus on analytical sciences at the University of Innsbruck/Austria in 1996. In the same year he started his work on Biosimilar medicines at Sandoz. He build up the analytical and pharmaceutical development departments for Sandoz' biopharmaceuticals in charge of the biosimilar pipeline and other biotech products of Sandoz. He moved from quality development into the regulatory and policy field in 2009 and since 2015 he is working as Chief Science Officer for Sandoz Biopharmaceuticals.
Mark Your Calendars Now!
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October